External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator
AUTOR(ES)
Asada, Shinichi
FONTE
The National Academy of Sciences
RESUMO
Overproduction of the Her2 oncoprotein has been found in ≈30% of breast tumors, and patients who have Her2 excesses typically have more aggressive disease. Here we show that the expression of the Her2 gene can be decreased by inhibiting the interaction of the two cancer-linked proteins, DRIP130/CRSP130/Sur-2 (a Ras-linked subunit of human mediator complexes) and ESX (an epithelial-restricted transcription factor). Disruption of the interaction by a short cell-permeable peptide reduced the expression of the Her2 gene and specifically impaired the growth and viability of Her2-overexpressing breast cancer cells. The association of ESX with DRIP130 is mediated by a small hydrophobic face of an 8-aa helix in ESX, suggesting a therapeutic approach to incapacitating the Her2 gene by small organic molecules.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=130531Documentos Relacionados
- HER2 expression in cervical cancer as a potential therapeutic target
- HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER
- HER2 status in breast cancer—an example of pharmacogenetic testing
- Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer
- HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin Phosphorylation*